Is the first postpartum drug priced too high?

Should Alzheimer’s researchers just give up on amyloid plaques? What will a new drug mean for moms with postpartum depression? And which coastal region of Long Island is superior?

Find out all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First up, STAT senior science writer Sharon Begley helps break down the very big and very disappointing news about the failure of Biogen’s closely watched experimental Alzheimer’s treatment, known as aducanumab. Next, Sage Therapeutics CEO Jeff Jonas calls in to talk about his company’s approval this week for a new drug for postpartum depression, for which Sage will charge $34,000. Finally, Jeff sticks around for a special lightning round in which we make him weigh in on Theranos villain Elizabeth Holmes and the New England Patriots, among other topics.

You can listen to the episode here. To listen to future episodes, be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.